TrialArthritis research & therapy2014

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis.

Maria Greenwald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.